News About: Pharm. Industry


Hanmi’s Poziotinib proved innovative efficacy for NSCLC patients

The advanced clinical result of ‘Poziotinib,’ a novel anticancer drug developed by Hanmi Pharm and licensed to Spectrum Pharmaceuticals, was revealed on the 18th at the World Conference on Lung Cancer(WCLC) in Yokoham...

Series of administrative measures on multinational pharmas for violating Pharmaceutical Affairs Law

Multinational pharmaceutical companies branching in Korea have frequently received administrative measures, such as sales suspension and advertising suspension, for violating the Pharmaceutical Affairs Law. According...

Celltrion, “We’re preparing for the U.S. FDA’s onsite inspection for our first global generic”

In response to the Korea Exchange’s request of inquiry notice on the 17th, Celltrion officially announced on the 18th “We carefully reviewed each item on Paragraph 1 of Article 6 of the KOSDAQ’s Posting Regulations an...

KPBMA gradually introduce ISO 37001 starting with chairmen’s companies

In order to address distrust of the Korean pharmaceutical industry in rebates, they decided to carry out the ISO 37001 certification starting with the association chairmen’s companies. Moreover, they also decided to ...

Drug price negotiation for lung cancer treatment ‘Tagrisso’ failed

The drug price negotiation of ‘Tagrisso,’ a new lung cancer drug of AstraZeneca, a multinational pharmaceutical company, was delayed for a week due to the Ministry of Health and Welfare’s order to suspend negotiation,...

Pharma industry sensitive over ‘secret survey for rebates’

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association will hold a board meeting on the 17th. The board meeting is the first meeting after the appointment of Chairman Hee-Mok Won since the last board meeti...

Myungmoon Pharm starts to sell ‘Creon’ under co-promotion agreement with Abott Korea

Myungmoon Pharm will sell ‘Creon,’ a Abott Korea’s pancreatic enzyme replacement therapy(PERT). Myungmoon Pharm(CEO Seok-Min Woo, Chun-Shik Park) and Aboot Korea(CEO Seung-Yoon Lee) recently signed a co-promotion agr...

Korean pharma industry encroach by multinational companies, only 23% of them were pure Korean medicines

Despite the government’s pharmaceutical industry nurturing policy, major value-added medicine markets in Korea have been encroached by multinational pharmaceutical companies. According to the materials that the Healt...

Abott’s new partner for digestive disorder treatment, ‘Green Cross’

Abott and Green Cross have attracted the industry as establishing a common front in the Korean digestive disorder treatment market. ‘Ganaton Tab’ Abott Korea has directly sold after acquiring its license from a Korea...

Rebates were increased instead? Needing special measures for this

Despite pharmaceutical companies’ efforts of eradicating rebates through ethical business management, the number of illegal rebate offenders were increasing for the past 3 years and there have been still reportedly a ...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.